ReviewHuman vaccines & immunotherapeutics2021

Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases.

Aishwarya Mary Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.